Concepedia
Statistics
Publications
19
Citations
1.4K
H-Index
17
Active since
1993
Affiliations
Eli Lilly (United States)(Current)
McGill University
Jewish General Hospital
Susan E. Pratt is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and oncology.
Publications per year
1993–2017
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites
Susan E. Pratt, Robert L. Shepard, Ramani A. Kandasamy et al. · Molecular Cancer Therapeutics · 2005 · 261 citations
Medicine, Oncology, Pharmacology +17
Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities
Anne H. Dantzig, Robert L. Shepard, K L Law et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 179 citations · Full text
Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media.
Susan E. Pratt, Michaël Pollak · PubMed · 1993 · 120 citations
Life Sciences, Endocrinology, Oncology +14
Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays
George E. Sandusky, Karen Mintze, Susan E. Pratt et al. · Histopathology · 2002 · 118 citations
Medicine, Oncology, Pathology +13
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks et al. · Molecular Cancer Therapeutics · 2013 · 116 citations
Medicine, Oncology, Pharmacology +13
1–5 of 19